J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 11, Number 9, September 2019, pages 642-650

Assessment of Gap Junction Protein Beta-2 rs3751385 Gene Polymorphism in Psoriasis Vulgaris

**Table 1.** Characteristics of Patients With Psoriasis and Healthy Controls
	Patients	Controls	P value
Hardy-Weinberg equilibrium. Controls: χ² = 0.341, df = 1, P = 0.559. Patients: χ² = 0.086, df = 1, P = 0.769.
No.	173	171
Age (years; mean ± SD)	48.97 ± 16.06	48.56 ± 15.96	0.810
Gender			0.884
Male	111 (64.2%)	111 (64.9%)
Female	62 (35.8%)	60 (35.1%)
Age onset
Early	108 (62.4%)	-
Late	65 (37.6%)	-

Table 1. Characteristics of Patients With Psoriasis and Healthy Controls

Patients

Controls

P value

Hardy-Weinberg equilibrium. Controls: χ² = 0.341, df = 1, P = 0.559. Patients: χ² = 0.086, df = 1, P = 0.769.

No.

173

171

Age (years; mean ± SD)

48.97 ± 16.06

48.56 ± 15.96

0.810

Gender

0.884

Male

111 (64.2%)

111 (64.9%)

Female

62 (35.8%)

60 (35.1%)

Age onset

Early

108 (62.4%)

Late

65 (37.6%)

**Table 2.** Distribution of GJB-2 SNP Genotypes Among Patients With Psoriasis and Healthy Controls According to Subject’s Gender
	Controls*	Patients*	OR^†	95% CI	P value
Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with psoriasis vulgaris and healthy controls: 1) χ² = 3.033, df = 2, P = 0.219; χ² = 2.913, df = 1, P = 0.088; χ² = 2.919, df = 1, P = 0.088 among the entire cohort; 2) χ² = 1.164, df = 2, P = 0.559; χ² =1 .108, df = 1, P = 0.293; χ² = 0.883, df = 1, P = 0.347 among males; 3) χ² = 2.630, df = 2, P = 0.269; χ² = 2.109, df = 1, P = 0.146; χ² = 2.455, df = 1, P = 0.117 among females. *Data are number of subjects and percentage (%). ^†Adjusted for age and gender. OR: odds ratio; CI: confidence interval.
Total
Genotype
C/C	111 (64.9%)	127 (73.4%)	Ref.
C/T	55 (32.2%)	43 (24.9%)	0.68	0.42 - 1.10	0.113
T/T	5 (2.9%)	3 (1.7%)	0.51	0.12 - 2.21	0.372
Recessive model
C/C	111 (64.9%)	127 (73.4%)	Ref.
C/T or T/T	60 (35.1%)	46 (26.6%)	0.67	0.42 - 1.06	0.087
Allele contrast
C	277 (81.0%)	297 (85.8%)	Ref.
T	65 (19.0%)	49 (14.2%)	0.70	0.47 - 1.05	0.086
Males
Genotype
C/C	77 (69.4%)	84 (75.7%)	Ref.
C/T	32 (28.8%)	25 (22.5%)	0.72	0.39 - 1.32	0.283
T/T	2 (1.8%)	2 (1.8%)	0.92	0.13 - 6.69	0.931
Recessive model
C/C	77 (69.4%)	84 (75.7%)	Ref.
C/T or T/T	34 (30.6%)	27 (24.3%)	0.73	0.40 - 1.32	0.293
Allele contrast
C	186 (83.8%)	193 (86.9%)	Ref.
T	36 (16.2%)	29 (13.1%)	0.78	0.46 - 1.32	0.349
Females
Genotype
C/C	34 (56.7%)	43 (69.4%)	Ref.
C/T	23 (38.3%)	18 (29.0%)	0.62	0.29 - 1.34	0.227
T/T	3 (5.0%)	1 (1.6%)	0.26	0.03 - 2.64	0.256
Recessive model
C/C	34 (56.7%)	43 (69.4%)	Ref.
C/T or T/T	26 (43.3%)	19 (30.6%)	0.58	0.28 - 1.22	0.153
Allele contrast
C	91 (75.8%)	104 (83.9%)	Ref.
T	29 (24.2%)	20 (16.1%)	0.61	0.32 - 1.15	0.123

Table 2. Distribution of GJB-2 SNP Genotypes Among Patients With Psoriasis and Healthy Controls According to Subject’s Gender

Controls*

Patients*

OR^†

95% CI

P value

Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with psoriasis vulgaris and healthy controls: 1) χ² = 3.033, df = 2, P = 0.219; χ² = 2.913, df = 1, P = 0.088; χ² = 2.919, df = 1, P = 0.088 among the entire cohort; 2) χ² = 1.164, df = 2, P = 0.559; χ² =1 .108, df = 1, P = 0.293; χ² = 0.883, df = 1, P = 0.347 among males; 3) χ² = 2.630, df = 2, P = 0.269; χ² = 2.109, df = 1, P = 0.146; χ² = 2.455, df = 1, P = 0.117 among females. *Data are number of subjects and percentage (%). ^†Adjusted for age and gender. OR: odds ratio; CI: confidence interval.

Total

Genotype

C/C

111 (64.9%)

127 (73.4%)

Ref.

C/T

55 (32.2%)

43 (24.9%)

0.68

0.42 - 1.10

0.113

T/T

5 (2.9%)

3 (1.7%)

0.51

0.12 - 2.21

0.372

Recessive model

C/C

111 (64.9%)

127 (73.4%)

Ref.

C/T or T/T

60 (35.1%)

46 (26.6%)

0.67

0.42 - 1.06

0.087

Allele contrast

277 (81.0%)

297 (85.8%)

Ref.

65 (19.0%)

49 (14.2%)

0.70

0.47 - 1.05

0.086

Males

Genotype

C/C

77 (69.4%)

84 (75.7%)

Ref.

C/T

32 (28.8%)

25 (22.5%)

0.72

0.39 - 1.32

0.283

T/T

2 (1.8%)

0.92

0.13 - 6.69

0.931

Recessive model

C/C

77 (69.4%)

84 (75.7%)

Ref.

C/T or T/T

34 (30.6%)

27 (24.3%)

0.73

0.40 - 1.32

0.293

Allele contrast

186 (83.8%)

193 (86.9%)

Ref.

36 (16.2%)

29 (13.1%)

0.78

0.46 - 1.32

0.349

Females

Genotype

C/C

34 (56.7%)

43 (69.4%)

Ref.

C/T

23 (38.3%)

18 (29.0%)

0.62

0.29 - 1.34

0.227

T/T

3 (5.0%)

1 (1.6%)

0.26

0.03 - 2.64

0.256

Recessive model

C/C

34 (56.7%)

43 (69.4%)

Ref.

C/T or T/T

26 (43.3%)

19 (30.6%)

0.58

0.28 - 1.22

0.153

Allele contrast

91 (75.8%)

104 (83.9%)

Ref.

29 (24.2%)

20 (16.1%)

0.61

0.32 - 1.15

0.123

**Table 3.** Distribution of GJB-2 SNP Genotypes Among Patients With Early-Onset Psoriasis and Healthy Controls According to Subject’s Gender
	Controls*	Early onset*	OR^†	95% CI	P value
Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with early onset psoriasis and healthy controls: 1) χ² = 2.047, df = 2, P = 0.359; χ² = 1.227, df = 1, P = 0.268; χ² = 1.619, df = 1, P = 0.203 among the entire cohort; 2) χ² = 0.047, df = 2, P = 0.977; χ² = 0.000, df = 1, P = 0.991; χ² = 0.004, df = 1, P = 0.951 among males; 3) χ² = 4.190, df = 2, P = 0.123; χ² = 3.264, df = 1, P = 0.071; χ² = 3.858, df = 1, P = 0.049 among females. *Data are number of subjects and percentage (%). ^†Adjusted for age and gender. ^‡Statistically significant P values. OR: odds ratio; CI: confidence interval.
Total
Genotype
C/C	111 (64.9%)	77 (71.3%)	Ref.^†
C/T	55 (32.2%)	30 (27.8%)	0.76	0.44 - 1.32	0.331
T/T	5 (2.9%)	1 (0.9%)	0.34	0.04 - 3.11	0.336
Recessive model
C/C	111 (64.9%)	77 (71.3%)	Ref.
C/T or T/T	60 (35.1%)	31 (28.7%)	0.73	0.42 - 1.26	0.254
Allele contrast
C	277 (81.0%)	184 (85.2%)	Ref.
T	65 (19.0%)	32 (14.8%)	0.74	0.46 - 1.19	0.216
Males
Genotype
C/C	77 (69.4%)	50 (69.4%)	Ref.
C/T	32 (28.8%)	21 (29.2%)	1.04	0.53 - 2.05	0.914
T/T	2 (1.8%)	1 (1.4%)	0.95	0.08 - 12.07	0.968
Recessive model
C/C	77 (69.4%)	50 (69.4%)	Ref.
C/T or T/T	34 (30.6%)	22 (30.6%)	1.03	0.53 - 2.02	0.923
Allele contrast
C	186 (83.8%)	121 (84.0%)	Ref.
T	36 (16.2%)	23 (16.0%)	1.02	0.57 - 1.85	0.940
Females
Genotype
C/C	34 (56.7%)	27 (75.0%)	Ref.
C/T	23 (38.3%)	9 (25.0%)	0.42	0.16 - 1.09	0.076
T/T	3 (5.0%)	0 (0.0%)	-	-	-
Recessive model
C/C	34 (56.7%)	27 (75.0%)	Ref.
C/T or T/T	26 (43.3%)	9 (25.0%)	0.44	0.18 - 1.08	0.074
Allele contrast
C	91 (75.8%)	63 (87.5%)	Ref.
T	29 (24.2%)	9 (12.5%)	0.41	0.18 - 0.95	0.038^‡

Table 3. Distribution of GJB-2 SNP Genotypes Among Patients With Early-Onset Psoriasis and Healthy Controls According to Subject’s Gender

Controls*

Early onset*

OR^†

95% CI

P value

Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with early onset psoriasis and healthy controls: 1) χ² = 2.047, df = 2, P = 0.359; χ² = 1.227, df = 1, P = 0.268; χ² = 1.619, df = 1, P = 0.203 among the entire cohort; 2) χ² = 0.047, df = 2, P = 0.977; χ² = 0.000, df = 1, P = 0.991; χ² = 0.004, df = 1, P = 0.951 among males; 3) χ² = 4.190, df = 2, P = 0.123; χ² = 3.264, df = 1, P = 0.071; χ² = 3.858, df = 1, P = 0.049 among females. *Data are number of subjects and percentage (%). ^†Adjusted for age and gender. ^‡Statistically significant P values. OR: odds ratio; CI: confidence interval.

Total

Genotype

C/C

111 (64.9%)

77 (71.3%)

Ref.^†

C/T

55 (32.2%)

30 (27.8%)

0.76

0.44 - 1.32

0.331

T/T

5 (2.9%)

1 (0.9%)

0.34

0.04 - 3.11

0.336

Recessive model

C/C

111 (64.9%)

77 (71.3%)

Ref.

C/T or T/T

60 (35.1%)

31 (28.7%)

0.73

0.42 - 1.26

0.254

Allele contrast

277 (81.0%)

184 (85.2%)

Ref.

65 (19.0%)

32 (14.8%)

0.74

0.46 - 1.19

0.216

Males

Genotype

C/C

77 (69.4%)

50 (69.4%)

Ref.

C/T

32 (28.8%)

21 (29.2%)

1.04

0.53 - 2.05

0.914

T/T

2 (1.8%)

1 (1.4%)

0.95

0.08 - 12.07

0.968

Recessive model

C/C

77 (69.4%)

50 (69.4%)

Ref.

C/T or T/T

34 (30.6%)

22 (30.6%)

1.03

0.53 - 2.02

0.923

Allele contrast

186 (83.8%)

121 (84.0%)

Ref.

36 (16.2%)

23 (16.0%)

1.02

0.57 - 1.85

0.940

Females

Genotype

C/C

34 (56.7%)

27 (75.0%)

Ref.

C/T

23 (38.3%)

9 (25.0%)

0.42

0.16 - 1.09

0.076

T/T

3 (5.0%)

0 (0.0%)

Recessive model

C/C

34 (56.7%)

27 (75.0%)

Ref.

C/T or T/T

26 (43.3%)

9 (25.0%)

0.44

0.18 - 1.08

0.074

Allele contrast

91 (75.8%)

63 (87.5%)

Ref.

29 (24.2%)

9 (12.5%)

0.41

0.18 - 0.95

0.038^‡

**Table 4.** Distribution of GJB-2 SNP Genotypes Among Patients With Late-Onset Psoriasis and Healthy Controls According to Subject’s Gender
	Controls*	Late onset*	OR^†	95% CI	P value
Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with late onset psoriasis and healthy controls: 1) χ² = 3.418, df = 2, P = 0.181; χ² = 3.134, df = 1, P = 0.077; χ² = 2.307, df = 1, P = 0.129 among the entire cohort; 2) χ² = 5.469, df = 2, P = 0.065; χ² = 4.758, df = 1, P = 0.029; χ² = 3.483, df = 1, P = 0.062 among males; 3) χ² = 0.193, df = 2, P = 0.908; χ² = 0.177, df = 1, P = 0.674; χ² = 0.185, df = 1, P = 0.668 among females. *Data are number of subjects and percentage (%). ^†Adjusted for age and gender. ^‡Statistically significant P values. OR: odds ratio; CI: confidence interval.
Total
Genotype
C/C	111 (64.9%)	50 (76.9%)	Ref.^†
C/T	55 (32.2%)	13 (20.0%)	0.56	0.26 - 1.19	0.134
T/T	5 (2.9%)	2 (3.1%)	0.64	0.10 - 3.96	0.632
Recessive model
C/C	111 (64.9%)	50 (76.9%)	Ref.
C/T or T/T	60 (35.1%)	15 (23.1%)	0.57	0.27 - 1.17	0.127
Allele contrast
C	277 (81.0%)	113 (86.9%)	Ref.
T	65 (19.0%)	17 (13.1%)	0.63	0.33 - 1.19	0.155
Males
Genotype
C/C	77 (69.4%)	34 (87.2%)	Ref.
C/T	32 (28.8%)	4 (10.3%)	0.22	0.07 - 0.77	0.017^‡
T/T	2 (1.8%)	1 (2.6%)	0.43	0.03 - 6.71	0.547
Recessive model
C/C	77 (69.4%)	34 (87.2%)	Ref.
C/T or T/T	34 (30.6%)	5 (12.8%)	0.24	0.08 - 0.77	0.016^‡
Allele contrast
C	186 (83.8%)	72 (92.3%)	Ref.
T	36 (16.2%)	6 (7.7%)	0.31	0.12 - 0.85	0.023^‡
Females
Genotype
C/C	34 (56.7%)	16 (61.5%)	Ref.
C/T	23 (38.3%)	9 (34.6%)	1.37	0.45 - 4.19	0.583
T/T	3 (5.0%)	1 (3.8%)	0.99	0.09 - 11.68	0.999
Recessive model
C/C	34 (56.7%)	16 (61.5%)	Ref.
C/T or T/T	26 (43.3%)	10 (38.5%)	1.32	0.45 - 3.86	0.618
Allele contrast
C	91 (75.8%)	41 (78.8%)	Ref.
T	29 (24.2%)	11 (21.1%)	1.18	0.49 - 2.82	0.668

Table 4. Distribution of GJB-2 SNP Genotypes Among Patients With Late-Onset Psoriasis and Healthy Controls According to Subject’s Gender

Controls*

Late onset*

OR^†

95% CI

P value

Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with late onset psoriasis and healthy controls: 1) χ² = 3.418, df = 2, P = 0.181; χ² = 3.134, df = 1, P = 0.077; χ² = 2.307, df = 1, P = 0.129 among the entire cohort; 2) χ² = 5.469, df = 2, P = 0.065; χ² = 4.758, df = 1, P = 0.029; χ² = 3.483, df = 1, P = 0.062 among males; 3) χ² = 0.193, df = 2, P = 0.908; χ² = 0.177, df = 1, P = 0.674; χ² = 0.185, df = 1, P = 0.668 among females. *Data are number of subjects and percentage (%). ^†Adjusted for age and gender. ^‡Statistically significant P values. OR: odds ratio; CI: confidence interval.

Total

Genotype

C/C

111 (64.9%)

50 (76.9%)

Ref.^†

C/T

55 (32.2%)

13 (20.0%)

0.56

0.26 - 1.19

0.134

T/T

5 (2.9%)

2 (3.1%)

0.64

0.10 - 3.96

0.632

Recessive model

C/C

111 (64.9%)

50 (76.9%)

Ref.

C/T or T/T

60 (35.1%)

15 (23.1%)

0.57

0.27 - 1.17

0.127

Allele contrast

277 (81.0%)

113 (86.9%)

Ref.

65 (19.0%)

17 (13.1%)

0.63

0.33 - 1.19

0.155

Males

Genotype

C/C

77 (69.4%)

34 (87.2%)

Ref.

C/T

32 (28.8%)

4 (10.3%)

0.22

0.07 - 0.77

0.017^‡

T/T

2 (1.8%)

1 (2.6%)

0.43

0.03 - 6.71

0.547

Recessive model

C/C

77 (69.4%)

34 (87.2%)

Ref.

C/T or T/T

34 (30.6%)

5 (12.8%)

0.24

0.08 - 0.77

0.016^‡

Allele contrast

186 (83.8%)

72 (92.3%)

Ref.

36 (16.2%)

6 (7.7%)

0.31

0.12 - 0.85

0.023^‡

Females

Genotype

C/C

34 (56.7%)

16 (61.5%)

Ref.

C/T

23 (38.3%)

9 (34.6%)

1.37

0.45 - 4.19

0.583

T/T

3 (5.0%)

1 (3.8%)

0.99

0.09 - 11.68

0.999

Recessive model

C/C

34 (56.7%)

16 (61.5%)

Ref.

C/T or T/T

26 (43.3%)

10 (38.5%)

1.32

0.45 - 3.86

0.618

Allele contrast

91 (75.8%)

41 (78.8%)

Ref.

29 (24.2%)

11 (21.1%)

1.18

0.49 - 2.82

0.668